



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

04 Nov 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date**

Important notices

- Significant Changes: FY 2016 NIH Grants Policy Statement ([NOT-OD-16-017](#))
- Request for Information: Randomized Controlled Trials (RCTs) of Lifestyle Weight Loss Interventions for Genome Wide Association Studies ([NOT-CA-15-042](#))
- NHLBI Announces Interest in R01 Studies Addressing the Epidemiology of HIV-Related Heart, Lung, and Blood Diseases and Sleep Disorders for PAR-15-280 "Multidisciplinary Studies of HIV/AIDS and Aging (R01)" ([NOT-HL-15-278](#))
- NHLBI Announces Interest in Omics-Related R01 Applications for RFA-HL-14-024 "Basic Research in the Pathogenesis of HIV-Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01)" ([NOT-HL-15-280](#))
- NHLBI Announces Interest in Epidemiology-Related R01 Applications for RFA-HL-14-023 "Clinical Research in the Prevention, Diagnosis, and Treatment of HIV-Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01)" ([NOT-HL-15-281](#))

1. Title: International Centers of Excellence for Malaria Research

Letter of Intent due date: March 15, 2016

Hyperlink: [\(RFA-AI-15-056\)](#)

Type: U19

Application Due Date: April 15, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Internal Submission will be 2 days before the application due date above.

Purpose: This Funding Opportunity Announcement (FOA) solicits applications to participate in an International Centers of Excellence for Malaria Research (ICEMR) program that will provide a multidisciplinary research approach to malaria control and prevention through the integration of findings from clinical and field research. The overarching goal of the ICEMR program is to establish research centers in malaria-endemic settings that will provide the necessary knowledge, tools, and evidence-based strategies for use by government organizations and health care institutions to control and treat malaria. This program is not intended to support research which can be conducted primarily in U.S. institutions.

Budget: The budget for each ICEMR cannot exceed \$1 million in direct costs per year excluding consortia F&A costs. It is required that at least 50% of the annual direct costs should be committed for field work and related research activities at the endemic sites. Awards are contingent upon the availability of funds and submission of a sufficient number of meritorious applications. An applicant may request a project period of up to 7 years.

2. Title: Metabolomics Data Analysis

Letter of Intent due date: January 11, 2016

Hyperlink: [\(RFA-RM-15-021\)](#)

Type: RO3

Application Due Date: February 11, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: The purpose of this small research grant Funding Opportunity Announcement (FOA) is to foster collaboration between bioinformaticians, metabolomics experts, and/or biomedical researchers in efforts to improve the ability to analyze metabolomics data to address biomedical questions. It is also expected that these grants would complement the current efforts of the [Common Fund Metabolomics Program](#) and maximize the value of existing metabolomics databases and resources.

Budget: Application budgets are limited to \$100,000 direct costs, but need to reflect the actual needs of the proposed project. The maximum project period is 1 year.



3. Title: Innovative Questions in Symptom Science and Genomics**Letter of Intent due date:** 30 days prior to application due date**Hyperlink:** [\(PA-16-023\)](#)
[\(PA-16-024\)](#)**Type:** R21
RO1

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: This initiative seeks to optimize innovation, insight and cutting edge conceptual and technological breakthroughs by catalyzing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.

Budget: R21: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **RO1:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Title: Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases**Letter of Intent due date:** 30 days prior to application due date**Hyperlink:** [\(PAR-16-020\)](#)**Type:** UO1

Application Due Date: February 18, 2016; August 18, 2016; February 17, 2017; August 17, 2017; February 15, 2018; August 17, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients. Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years

5. Title: NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders**Letter of Intent due date:** 30 days prior to application due date**Hyperlink:** [\(PAR-16-021\)](#)**Type:** XO1

Application Due Date: January 19, 2016; January 19, 2017; January 19, 2018; January 18, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP.

Budget: Not applicable. Funds are not awarded via this XO1 resource access award. The maximum project period is 4 years.

6. Title: HIV/AIDS High Priority Drug Abuse Research**Letter of Intent due date:** 30 days prior to application due date**Hyperlink:** [\(PAS-16-018\)](#)**Type:** RO1

Application Due Date: [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: The National Institutes of Health has recently announced the HIV/AIDS research priorities for the next three to five years <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html>. The goal of this Funding Opportunity Announcement (FOA) is to stimulate high priority research relevant to drug abuse and HIV/AIDS.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

X01 - Resource Access Award: A Program to invite eligible institutions to seek access to NIH research resources. This includes programs where institutions will request access to submit to the resource, e.g., high throughput screening assays. It also includes programs where access to a specific NIH research resource is needed to conduct certain research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

U19 - Research Program – Cooperative Agreements: To support a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective. Substantial Federal programmatic staff involvement is intended to assist investigators during performance of the research activities, as defined in the terms and conditions of award. The investigators have primary authorities and responsibilities to define research objectives and approaches, and to plan, conduct, analyze, and publish results, interpretations and conclusions of their studies. Each research project is usually under the leadership of an established investigator in an area representing his/her special interest and competencies. Each project supported through this mechanism should contribute to or be directly related to the common theme of the total research effort. The award can provide support for certain basic shared resources, including clinical components, which facilitate the total research effort. These scientifically meritorious projects should demonstrate an essential element of unity and interdependence.

Complete [Glossary and acronym list of NIH Terms](#)